Hints and tips:
Related Special Reports
...The practice is currently limited to a small number of companies, including Illumina and Allelica, and its use is not yet widespread....
...Its specific funding demands are limited and it will not contain a mechanism to hold countries accountable for breaching it....
...She also points out that luxury groups are making strides in the entertainment industry....
...Once it gets into its stride, however, Death in the Blood becomes a gripping narrative, strengthened by Wheeler’s longstanding connection to the story....
...Need to know: UK and Europe economy UK chancellor Jeremy Hunt’s hopes of offering big pre-election tax cuts have hit a snag: internal Treasury forecasts suggest he will have only limited scope for giveaways...
...Regulators have taken notice after a study sparked fresh doubts over the usefulness of a Covid drug made by US pharma group Merck, raising questions about the costly procurement of antivirals during the...
...Says a company spokesperson: “We wanted to turn science fiction into science reality.”...
...But Cambridge’s expertise in artificial intelligence, antibodies, and cell and gene therapies had now attracted both Big Tech and Big Pharma....
...It makes no commercial sense to invest heavily in drugs whose time on the market will be limited....
...Nathalie Moll, director-general of lobby group EFPIA, said the law puts a “straitjacket on European science, research and development”....
...The same complaints can be heard across the innovation industries, including medtech and pharma....
...Yet despite a 2014 partnership with US pharma company AbbVie, extended in 2021, Calico has yet to bring any drugs to the market....
...Susanne Fiedler, chief commercial officer of Merck spin-off Organon, said investors often assumed that women’s specific health needs were limited to reproductive health, whereas common autoimmune and cardiac...
...A BMS spokeswoman says: “protection of the intellectual property enables our ability to keep pushing the boundaries of science”....
...This is reducing net prices for pharma groups’ products even as they grapple with cost inflation — and when life sciences ingenuity produced the vaccines that tamed Covid....
...Under the proposed reforms, Medicare, the US taxpayer-funded healthcare scheme for retirees, would be allowed to negotiate prices for a limited number of branded medicines....
...“The market remains nonplussed with Pfizer’s post-Covid story and limited business development in 2022,” said Evan Seigerman, analyst at BMO Capital Markets....
...Elizabeth Anderson, an analyst at Evercore, said large pharma companies are not generally sensitive to NHP pricing but over the long-term high prices and supply disruption could prompt them to invest in...
...A Biogen drug called aducanumab was the first drug to be approved by US regulators last year, though its benefits appear limited and US insurers refuse to pay for it....
...Her approach to foreign and economic policy, two areas where she had limited experience before arriving in Washington, will be especially scrutinised....
...Science round-up FT science commentator Anjana Ahuja discusses a controversial new surgical procedure dubbed “partial resurrection”, which involves restarting limited blood circulation in organ donors who...
...to Gilead Sciences for $12bn in 2017....
...And while successive varieties of Conservative government have trumpeted the UK’s life sciences industry as terribly important, the results on the ground are underwhelming....
...“How do we prevent it from becoming classic pharma, and keep the public mission going? Well, the answer is it’s very, very hard, and it’s not clear.”...
...German pharma group Merck decided in 2020 to phase out animal testing, although it has not set a deadline for completion....
International Edition